<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30379" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Selective Serotonin Reuptake Inhibitor Toxicity</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bruggeman</surname>
            <given-names>Clare</given-names>
          </name>
          <aff>University Hospital St John&#x02019;s Westshore</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>O'Day</surname>
            <given-names>Carla S.</given-names>
          </name>
          <aff>University Hospital, St John Medical Cr</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Clare Bruggeman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Carla O'Day declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30379.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed antidepressants. Other clinical indications for SSRI use include anxiety disorders, obsessive-compulsive disorder, panic disorders, and eating disorders. Compared to their predecessors, the monoamine oxidase inhibitors and tricyclic antidepressants, SSRIs are associated with fewer toxic effects. This activity describes the uses, mode of action and adverse effects of SSRIs and highlights the role of the interprofessional team in the management of these patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mode of action of the SSRIs.</p></list-item><list-item><p>Review the toxic effects of SSRIs.</p></list-item><list-item><p>Summarize the treatment options of SSRI toxicity.</p></list-item><list-item><p>Outline interprofessional team strategies for improving care coordination and outcomes in patients with SSRI toxicity.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30379&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30379">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30379.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Selective&#x000a0;serotonin&#x000a0;reuptake&#x000a0;inhibitors (SSRIs) are commonly prescribed antidepressants. Other clinical indications for SSRI use&#x000a0;include anxiety disorders, obsessive-compulsive disorder, panic disorders, and eating disorders. Compared to their predecessors, the monoamine oxidase inhibitors and tricyclic antidepressants, SSRIs are associated with fewer toxic effects.<xref ref-type="bibr" rid="article-30379.r1">[1]</xref>&#x000a0;</p>
        <p>Individual SSRIs differ from each other regarding structure and pharmacokinetics but, as a group, they act by potentiating the action of serotonin. SSRIs are less cardiotoxic than many first-generation antidepressants, but there is still evidence that&#x000a0;they&#x000a0;inhibit sodium, calcium, and potassium ion channels at concentrations near&#x000a0;therapeutic levels.<xref ref-type="bibr" rid="article-30379.r2">[2]</xref>&#x000a0;Citalopram and escitalopram are known to&#x000a0;cause QTc prolongation.<xref ref-type="bibr" rid="article-30379.r3">[3]</xref><xref ref-type="bibr" rid="article-30379.r4">[4]</xref>&#x000a0;There also have been reports of atrial fibrillation and bradycardia related to fluoxetine use.<xref ref-type="bibr" rid="article-30379.r5">[5]</xref></p>
        <p>Adverse effects of SSRIs are vague and nonspecific but include hyponatremia, anorgasmia, sedation, stimulation, and gastric irritation.<xref ref-type="bibr" rid="article-30379.r6">[6]</xref><xref ref-type="bibr" rid="article-30379.r7">[7]</xref>&#x000a0;Seizures are uncommon but have been reported; Isbister et al.<xref ref-type="bibr" rid="article-30379.r8">[8]</xref> reported a seizure incidence of 1.9%. They may also inhibit platelet secretion, aggregation, and plug formation.<xref ref-type="bibr" rid="article-30379.r9">[9]</xref></p>
        <p>Patients with adverse effects from SSRIs will present with a range of symptoms, and some researchers have advocated for the term &#x0201c;serotonin toxicity&#x0201d; rather than &#x0201c;serotonin syndrome&#x0201d; to highlight that this condition is a spectrum of symptoms rather than a single clinical entity.&#x000a0;<xref ref-type="bibr" rid="article-30379.r10">[10]</xref><xref ref-type="bibr" rid="article-30379.r11">[11]</xref>&#x000a0;In patients with mild symptoms, the benefit they receive from the prescribed SSRI may outweigh the negative side effects.</p>
      </sec>
      <sec id="article-30379.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Serotonin toxicity is the most serious drug reaction from inadvertent or intentional SSRI overdose and can&#x000a0;be iatrogenic, caused&#x000a0;by the introduction of a serotonergic agent, increased dosing of an established serotonergic agent or after coadministration with another agent that increases serotonin activity.<xref ref-type="bibr" rid="article-30379.r12">[12]</xref>&#x000a0;The most severe cases&#x000a0;are caused&#x000a0;by combinations of drugs that enhance serotonin levels by acting through separate mechanisms, for example, a monoamine oxidase inhibitor and a serotonin reuptake inhibitor.<xref ref-type="bibr" rid="article-30379.r13">[13]</xref></p>
        <p>Many medications affect serotonin levels by different overlapping mechanisms.&#x000a0;In addition to&#x000a0;SSRIs, ondansetron, methadone,&#x000a0;clomipramine, amitriptyline, dextromethorphan, fentanyl, meperidine, tramadol, trazodone, venlafaxine, and pentazocine increase serotonin levels by blocking reuptake. Medications that can increase serotonin levels by inhibiting serotonin metabolism include&#x000a0;linezolid, methylene blue, St. John's wort, or&#x000a0;monoamine oxidase inhibitors like&#x000a0;phenelzine, selegiline, and isocarboxazid. Methylenedioxymethamphetamine (MDMA) and mirtazapine enhance serotonin release. Tryptophan&#x000a0;is a serotonin precursor. Cocaine increases serotonin synthesis.&#x000a0;Buspirone, fentanyl, dihydroergotamine, lithium, lysergic acid diethylamide (LSD), metoclopramide and&#x000a0;triptans&#x000a0;stimulate serotonin receptors.<xref ref-type="bibr" rid="article-30379.r12">[12]</xref><xref ref-type="bibr" rid="article-30379.r14">[14]</xref><xref ref-type="bibr" rid="article-30379.r15">[15]</xref><xref ref-type="bibr" rid="article-30379.r16">[16]</xref>&#x000a0;Research is still ongoing&#x000a0;on the subject of opioid&#x000a0;safety with concomitant SSRI.<xref ref-type="bibr" rid="article-30379.r17">[17]</xref><xref ref-type="bibr" rid="article-30379.r18">[18]</xref><xref ref-type="bibr" rid="article-30379.r19">[19]</xref>Studies have shown that synthetic opioids can inhibit SERT (serotonin transporter) but fentanyl and oxycodone, which have not shown inhibitory effects on SERT, have&#x000a0;been reported&#x000a0;anecdotally in&#x000a0;cases of serotonin toxicity.<xref ref-type="bibr" rid="article-30379.r20">[20]</xref><xref ref-type="bibr" rid="article-30379.r21">[21]</xref></p>
      </sec>
      <sec id="article-30379.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The American Association of Poison Control Centers reported over 50,000&#x000a0;overdose cases&#x000a0;in 2016 where SSRIs&#x000a0;were mentioned; of these reported cases, 102 were fatal, but in all but one of these fatalities&#x000a0;co-ingestants&#x000a0;were involved.<xref ref-type="bibr" rid="article-30379.r22">[22]</xref>&#x000a0;Sertraline and fluoxetine were the SSRIs most commonly taken in excess.<xref ref-type="bibr" rid="article-30379.r22">[22]</xref> One study analyzing 469 SSRI overdoses reported serotonin toxicity in 14% of cases.<xref ref-type="bibr" rid="article-30379.r8">[8]</xref></p>
      </sec>
      <sec id="article-30379.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Serotonin toxicity is a clinical diagnosis initially defined by the Sternbach criteria. Generally, these symptoms include neuromuscular excitation, autonomic stimulation and altered level of consciousness. The presence of generalized clonus&#x000a0;indicates&#x000a0;serotonin toxicity.<xref ref-type="bibr" rid="article-30379.r13">[13]</xref>&#x000a0;Neuromuscular symptoms are usually more prominent in the lower extremities.<xref ref-type="bibr" rid="article-30379.r15">[15]</xref></p>
        <p>Due to the nonspecific nature of the Sternbach criteria,&#x000a0;the Hunt serotonin toxicity criteria were developed. The Hunt serotonin toxicity criteria decision rule describes 5 constellations of symptoms that define&#x000a0;serotonin toxicity<xref ref-type="bibr" rid="article-30379.r10">[10]</xref>:</p>
        <list list-type="order">
          <list-item>
            <p>Spontaneous clonus</p>
          </list-item>
          <list-item>
            <p>Inducible clonus and agitation or diaphoresis</p>
          </list-item>
          <list-item>
            <p>Ocular clonus with agitation or diaphoresis</p>
          </list-item>
          <list-item>
            <p>Tremor and hyperreflexia</p>
          </list-item>
          <list-item>
            <p>Ocular clonus, hypertonicity, and temperature greater than 38 C</p>
          </list-item>
        </list>
        <p>Besides signs and symptoms, a history suggestive of serotonin exposure or overdose&#x000a0;is required&#x000a0;to diagnose serotonin toxicity.</p>
        <p>Minor symptoms of serotonin toxicity include&#x000a0;vomiting, somnolence, mydriasis, or diaphoresis.&#x000a0;Someone can see severe symptoms (decreased level of consciousness, ECG changes, and seizures&#x000a0;with overdoses greater than 75 times the recommended daily dose.<xref ref-type="bibr" rid="article-30379.r23">[23]</xref>&#x000a0;The concentration of the different serotonin receptors is highest in the neuromuscular, autonomic nervous, and gastrointestinal (GI) systems, accounting for the variety of common adverse effects of serotonin excess.<xref ref-type="bibr" rid="article-30379.r14">[14]</xref></p>
      </sec>
      <sec id="article-30379.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Initial evaluation and treatment of a patient with serotonin toxicity are&#x000a0;similar to&#x000a0;any overdose, altered mental status, or poisoning patient with the establishment of intravenous access, initiation of cardiac monitoring, stabilization of vital signs, and fluid resuscitation. Diagnosis of serotonin toxicity is not only clinical but also a diagnosis of exclusion, therefore, even though diagnosis does not rely on any specific laboratory value, thorough testing to rule out other causes of altered mental status is essential.<xref ref-type="bibr" rid="article-30379.r12">[12]</xref></p>
      </sec>
      <sec id="article-30379.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Nelson&#x000a0;et al.<xref ref-type="bibr" rid="article-30379.r24">[24]</xref>&#x000a0;established guidelines for out-of-hospital management of isolated SSRI overdose and recommended at-home observation of patients who were experiencing minor symptoms and had ingested less than 5 times their own prescribed dose or less than 5 times the initial adult dose in an SSRI-naive patient.&#x000a0;This should only be done&#x000a0;in close conjunction with a regional poison control center.</p>
        <p>Treatment is&#x000a0;largely&#x000a0;supportive and involves discontinuation of all serotonergic therapies, control of agitation with benzodiazepines and defervescence.<xref ref-type="bibr" rid="article-30379.r25">[25]</xref><xref ref-type="bibr" rid="article-30379.r12">[12]</xref>&#x000a0;Droperidol&#x000a0;and haloperidol should not be used to control agitation as these medications can worsen hyperthermia by inhibiting sweating through their anticholinergic properties.<xref ref-type="bibr" rid="article-30379.r26">[26]</xref></p>
        <p>In severe cases of serotonin toxicity where patients required endotracheal intubation and ventilatory support, hypertonicity, rigidity, and high-grade fever were evident.<xref ref-type="bibr" rid="article-30379.r12">[12]</xref></p>
        <p>Muscular rigidity&#x000a0;is thought&#x000a0;to be the primary cause of hyperthermia and death so patients with severe symptoms should&#x000a0;be rapidly cooled. If benzodiazepines do not sufficiently control muscle spasm or temperature is greater than 41.1 C,&#x000a0;intubation with neuromuscular blockade and paralysis can&#x000a0;be considered.<xref ref-type="bibr" rid="article-30379.r12">[12]</xref>&#x000a0;In cases&#x000a0;refractory to supportive care,&#x000a0;cyproheptadine or chlorpromazine, which have anti-serotonergic properties, can be administered; although, it is unclear if&#x000a0;these medications&#x000a0;alter patient outcome.<xref ref-type="bibr" rid="article-30379.r27">[27]</xref><xref ref-type="bibr" rid="article-30379.r28">[28]</xref>&#x000a0;Cyproheptadine does not have an IV formulation and must, therefore,&#x000a0;be administered&#x000a0;via a nasogastric or orogastric tube.<xref ref-type="bibr" rid="article-30379.r29">[29]</xref>&#x000a0;There is no role for acetaminophen, NSAIDs, or aspirin in control of hyperthermia as&#x000a0;the increased temperature&#x000a0;is not caused&#x000a0;by a change in the hypothalamic temperature set point.<xref ref-type="bibr" rid="article-30379.r27">[27]</xref></p>
      </sec>
      <sec id="article-30379.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Serotonin toxicity should not&#x000a0;be confused&#x000a0;with the neuroleptic malignant syndrome (NMS) which usually has an insidious onset of bradykinesia, "lead pipe"&#x000a0;rigidity and other extrapyramidal symptoms.<xref ref-type="bibr" rid="article-30379.r13">[13]</xref>&#x000a0;Duration of NMS is on the order of weeks, significantly longer than serotonin toxicity, which usually resolves within 24 hours of discontinuation of serotonergic therapies&#x000a0;<xref ref-type="bibr" rid="article-30379.r29">[29]</xref></p>
      </sec>
      <sec id="article-30379.s9" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Prognosis is good, and full&#x000a0;recovery is expected.<xref ref-type="bibr" rid="article-30379.r29">[29]</xref>&#x000a0;The median length of stay for these SSRI overdose admissions was 15.3 hours in one study.<xref ref-type="bibr" rid="article-30379.r8">[8]</xref>&#x000a0;Mild cases can&#x000a0;be observed&#x000a0;in the emergency department for&#x000a0;at least&#x000a0;6 hours before being discharged safely home.<xref ref-type="bibr" rid="article-30379.r12">[12]</xref>&#x000a0;Pharmacokinetics of the specific drug involved appear to affect duration; fluoxetine has a longer half-life than other SSRIs at&#x000a0;4 to&#x000a0;6 days.<xref ref-type="bibr" rid="article-30379.r7">[7]</xref><xref ref-type="bibr" rid="article-30379.r29">[29]</xref></p>
        <p>Patients with severe symptoms should be&#x000a0;dispositioned&#x000a0;to the intensive care unit.</p>
      </sec>
      <sec id="article-30379.s10" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>SSRIs are prescribed by many healthcare workers including the primary care provider, psychiatrist, pain specialist, and the nurse practitioner. Unlike their predecessors, the monoamine oxidase inhibitors and tricyclic antidepressants, SSRIs are much safer in overdose.<xref ref-type="bibr" rid="article-30379.r1">[1]</xref>&#x000a0; However, at the same time SSRIs are also associated with several serious adverse effects that need close monitoring. All clinicians who prescribe these drugs should educate the patient on the potential adverse effects. Nursing staff can also counsel the patients, monitor treatment effectiveness, watch for adverse drug reactions, and alert the prescriber regarding any issues that arise. In addition, the pharmacist has to make sure that the patient is not on any other medication that may lead to a drug-drug interaction with the SSRI.&#x000a0; More important the pharmacist should ensure that multiple clinicians do not prescribe similar agents leading to polypharmacy and report concerns to the clinical team. An interprofessional approach between clinicians and pharmacists working together will result in the best outcomes. [Level 5]</p>
        <p>Clear, closed-loop communication between pre-hospital, regional poison control center, emergency department, and intensive care staff is essential to make sure that patients prescribed SSRI receive the appropriate&#x000a0;level of care while safely allocating resources.<xref ref-type="bibr" rid="article-30379.r30">[30]</xref></p>
      </sec>
      <sec id="article-30379.s11">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30379&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30379">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/medications/selective-serotonin-reuptake-inhibitor-toxicity/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=30379">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30379/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30379">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30379.s12">
        <title>References</title>
        <ref id="article-30379.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McKenzie</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>McFarland</surname>
                <given-names>BH</given-names>
              </name>
            </person-group>
            <article-title>Trends in antidepressant overdoses.</article-title>
            <source>Pharmacoepidemiol Drug Saf</source>
            <year>2007</year>
            <month>May</month>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>513</fpage>
            <page-range>513-23</page-range>
            <pub-id pub-id-type="pmid">17200994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30379.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pacher</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kecskemeti</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?</article-title>
            <source>Curr Pharm Des</source>
            <year>2004</year>
            <volume>10</volume>
            <issue>20</issue>
            <fpage>2463</fpage>
            <page-range>2463-75</page-range>
            <pub-id pub-id-type="pmid">15320756</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30379.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hasnain</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Howland</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Vieweg</surname>
                <given-names>WV</given-names>
              </name>
            </person-group>
            <article-title>Escitalopram and QTc prolongation.</article-title>
            <source>J Psychiatry Neurosci</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>38</volume>
            <issue>4</issue>
            <fpage>E11</fpage>
            <pub-id pub-id-type="pmid">23791140</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30379.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vieweg</surname>
                <given-names>WV</given-names>
              </name>
              <name>
                <surname>Hasnain</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Howland</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Hettema</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Kogut</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Pandurangi</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling?</article-title>
            <source>Am J Med</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>125</volume>
            <issue>9</issue>
            <fpage>859</fpage>
            <page-range>859-68</page-range>
            <pub-id pub-id-type="pmid">22748401</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30379.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pacher</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ungvari</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Kecskemeti</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Furst</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Review of cardiovascular effects of fluoxetine, a selective serotonin reuptake inhibitor, compared to tricyclic antidepressants.</article-title>
            <source>Curr Med Chem</source>
            <year>1998</year>
            <month>Oct</month>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>381</fpage>
            <page-range>381-90</page-range>
            <pub-id pub-id-type="pmid">9756980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30379.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Varela Pi&#x000f1;&#x000f3;n</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ad&#x000e1;n-Manes</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Selective Serotonin Reuptake Inhibitor-Induced Hyponatremia: Clinical Implications and Therapeutic Alternatives.</article-title>
            <source>Clin Neuropharmacol</source>
            <year>2017</year>
            <season>Jul/Aug</season>
            <volume>40</volume>
            <issue>4</issue>
            <fpage>177</fpage>
            <page-range>177-179</page-range>
            <pub-id pub-id-type="pmid">28622213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30379.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marken</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Munro</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Selecting a Selective Serotonin Reuptake Inhibitor: Clinically Important Distinguishing Features.</article-title>
            <source>Prim Care Companion J Clin Psychiatry</source>
            <year>2000</year>
            <month>Dec</month>
            <volume>2</volume>
            <issue>6</issue>
            <fpage>205</fpage>
            <page-range>205-210</page-range>
            <pub-id pub-id-type="pmid">15014630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30379.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Isbister</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Bowe</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Dawson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Whyte</surname>
                <given-names>IM</given-names>
              </name>
            </person-group>
            <article-title>Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose.</article-title>
            <source>J Toxicol Clin Toxicol</source>
            <year>2004</year>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>277</fpage>
            <page-range>277-85</page-range>
            <pub-id pub-id-type="pmid">15362595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30379.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Halperin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Reber</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Influence of antidepressants on hemostasis.</article-title>
            <source>Dialogues Clin Neurosci</source>
            <year>2007</year>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <page-range>47-59</page-range>
            <pub-id pub-id-type="pmid">17506225</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30379.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dunkley</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Isbister</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Sibbritt</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dawson</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Whyte</surname>
                <given-names>IM</given-names>
              </name>
            </person-group>
            <article-title>The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity.</article-title>
            <source>QJM</source>
            <year>2003</year>
            <month>Sep</month>
            <volume>96</volume>
            <issue>9</issue>
            <fpage>635</fpage>
            <page-range>635-42</page-range>
            <pub-id pub-id-type="pmid">12925718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30379.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gillman</surname>
                <given-names>PK</given-names>
              </name>
            </person-group>
            <article-title>Serotonin syndrome: history and risk.</article-title>
            <source>Fundam Clin Pharmacol</source>
            <year>1998</year>
            <volume>12</volume>
            <issue>5</issue>
            <fpage>482</fpage>
            <page-range>482-91</page-range>
            <pub-id pub-id-type="pmid">9794145</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30379.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Volpi-Abadie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Serotonin syndrome.</article-title>
            <source>Ochsner J</source>
            <year>2013</year>
            <season>Winter</season>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>533</fpage>
            <page-range>533-40</page-range>
            <pub-id pub-id-type="pmid">24358002</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30379.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Isbister</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Whyte</surname>
                <given-names>IM</given-names>
              </name>
            </person-group>
            <article-title>Serotonin toxicity: a practical approach to diagnosis and treatment.</article-title>
            <source>Med J Aust</source>
            <year>2007</year>
            <month>Sep</month>
            <day>17</day>
            <volume>187</volume>
            <issue>6</issue>
            <fpage>361</fpage>
            <page-range>361-5</page-range>
            <pub-id pub-id-type="pmid">17874986</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30379.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frank</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Recognition and treatment of serotonin syndrome.</article-title>
            <source>Can Fam Physician</source>
            <year>2008</year>
            <month>Jul</month>
            <volume>54</volume>
            <issue>7</issue>
            <fpage>988</fpage>
            <page-range>988-92</page-range>
            <pub-id pub-id-type="pmid">18625822</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30379.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Foong</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Grindrod</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kellar</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Demystifying serotonin syndrome (or <italic>serotonin toxicity</italic>).</article-title>
            <source>Can Fam Physician</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>64</volume>
            <issue>10</issue>
            <fpage>720</fpage>
            <page-range>720-727</page-range>
            <pub-id pub-id-type="pmid">30315014</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30379.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bartlett</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Drug-Induced Serotonin Syndrome.</article-title>
            <source>Crit Care Nurse</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <page-range>49-54</page-range>
            <pub-id pub-id-type="pmid">28148614</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30379.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sundaramurthy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Annamalai</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Samuvel</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Shippenberg</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Jayanthi</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Ramamoorthy</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Modulation of serotonin transporter function by kappa-opioid receptor ligands.</article-title>
            <source>Neuropharmacology</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>113</volume>
            <issue>Pt A</issue>
            <fpage>281</fpage>
            <page-range>281-292</page-range>
            <pub-id pub-id-type="pmid">27743931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30379.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stamer</surname>
                <given-names>UM</given-names>
              </name>
              <name>
                <surname>Lyutenska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>St&#x000fc;ber</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>B&#x000f6;nisch</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Urban</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Effects of opioids on human serotonin transporters.</article-title>
            <source>Naunyn Schmiedebergs Arch Pharmacol</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>388</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <page-range>43-9</page-range>
            <pub-id pub-id-type="pmid">25332055</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30379.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rickli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Liakoni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hoener</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Liechti</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome.</article-title>
            <source>Br J Pharmacol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>175</volume>
            <issue>3</issue>
            <fpage>532</fpage>
            <page-range>532-543</page-range>
            <pub-id pub-id-type="pmid">29210063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30379.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gillman</surname>
                <given-names>PK</given-names>
              </name>
            </person-group>
            <article-title>Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.</article-title>
            <source>Br J Anaesth</source>
            <year>2005</year>
            <month>Oct</month>
            <volume>95</volume>
            <issue>4</issue>
            <fpage>434</fpage>
            <page-range>434-41</page-range>
            <pub-id pub-id-type="pmid">16051647</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30379.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baldo</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects.</article-title>
            <source>Arch Toxicol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>92</volume>
            <issue>8</issue>
            <fpage>2457</fpage>
            <page-range>2457-2473</page-range>
            <pub-id pub-id-type="pmid">29916050</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30379.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gummin</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Mowry</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Spyker</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Fraser</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Banner</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>2016 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 34th Annual Report.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>55</volume>
            <issue>10</issue>
            <fpage>1072</fpage>
            <page-range>1072-1252</page-range>
            <pub-id pub-id-type="pmid">29185815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30379.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barbey</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Roose</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>SSRI safety in overdose.</article-title>
            <source>J Clin Psychiatry</source>
            <year>1998</year>
            <volume>59 Suppl 15</volume>
            <fpage>42</fpage>
            <page-range>42-8</page-range>
            <pub-id pub-id-type="pmid">9786310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30379.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nelson</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Erdman</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Booze</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Cobaugh</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Chyka</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Woolf</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Scharman</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Wax</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Manoguerra</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Christianson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Caravati</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Troutman</surname>
                <given-names>WG</given-names>
              </name>
            </person-group>
            <article-title>Selective serotonin reuptake inhibitor poisoning: An evidence-based consensus guideline for out-of-hospital management.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2007</year>
            <month>May</month>
            <volume>45</volume>
            <issue>4</issue>
            <fpage>315</fpage>
            <page-range>315-32</page-range>
            <pub-id pub-id-type="pmid">17486478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30379.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nisijima</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shioda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yoshino</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takano</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Diazepam and chlormethiazole attenuate the development of hyperthermia in an animal model of the serotonin syndrome.</article-title>
            <source>Neurochem Int</source>
            <year>2003</year>
            <month>Jul</month>
            <volume>43</volume>
            <issue>2</issue>
            <fpage>155</fpage>
            <page-range>155-64</page-range>
            <pub-id pub-id-type="pmid">12620284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30379.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanii</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Taniguchi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Niigawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hosono</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ikura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sakamoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kudo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nishimura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takeda</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Development of an animal model for neuroleptic malignant syndrome: heat-exposed rabbits with haloperidol and atropine administration exhibit increased muscle activity, hyperthermia, and high serum creatine phosphokinase level.</article-title>
            <source>Brain Res</source>
            <year>1996</year>
            <month>Dec</month>
            <day>16</day>
            <volume>743</volume>
            <issue>1-2</issue>
            <fpage>263</fpage>
            <page-range>263-70</page-range>
            <pub-id pub-id-type="pmid">9017254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30379.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eyer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zilker</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Bench-to-bedside review: mechanisms and management of hyperthermia due to toxicity.</article-title>
            <source>Crit Care</source>
            <year>2007</year>
            <volume>11</volume>
            <issue>6</issue>
            <fpage>236</fpage>
            <pub-id pub-id-type="pmid">18096088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30379.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Graudins</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stearman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Treatment of the serotonin syndrome with cyproheptadine.</article-title>
            <source>J Emerg Med</source>
            <year>1998</year>
            <season>Jul-Aug</season>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>615</fpage>
            <page-range>615-9</page-range>
            <pub-id pub-id-type="pmid">9696181</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30379.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Birmes</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Coppin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schmitt</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lauque</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Serotonin syndrome: a brief review.</article-title>
            <source>CMAJ</source>
            <year>2003</year>
            <month>May</month>
            <day>27</day>
            <volume>168</volume>
            <issue>11</issue>
            <fpage>1439</fpage>
            <page-range>1439-42</page-range>
            <pub-id pub-id-type="pmid">12771076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30379.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stoner</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Marken</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Switzer</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Barber</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Sommi</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Steele</surname>
                <given-names>MT</given-names>
              </name>
            </person-group>
            <article-title>Antidepressant overdoses and resultant emergency department services: the impact of SSRIs.</article-title>
            <source>Psychopharmacol Bull</source>
            <year>1997</year>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>667</fpage>
            <page-range>667-70</page-range>
            <pub-id pub-id-type="pmid">9493477</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
